Clinical Pharmacology of Intranasal Biologic Drug Delivery Systems

Abstract

Intranasal biologic drug delivery systems represent a significant innovation in clinical pharmacology, offering targeted, efficient, and patient-friendly alternatives to traditional administration routes for various biologics. This review comprehensively explores the mechanistic basis, epidemiological context, clinical applications, and recent advances in intranasal delivery of biologics, integrating current research evidence and clinical guidelines. The article highlights the unique anatomical and physiological properties of the nasal cavity, the role of these systems in treating neurological, immunological, and systemic diseases, as well as the risks, benefits, and future perspectives of intranasal biologic therapeutics.

Introduction

Biologic drugs—encompassing monoclonal antibodies, peptides, proteins, and nucleic acid-based therapies—have transformed the therapeutic landscape for numerous medical conditions. Traditional administration routes, such as intravenous or subcutaneous injection, are often limited by systemic side effects, poor patient compliance, and barriers to central nervous system (CNS) delivery. Intranasal drug delivery (INDD) emerges as a promising modality, leveraging the unique vascularization and permeability of the nasal mucosa to enable rapid, non-invasive, and, in some cases, direct CNS drug access. This review aims to provide clinicians and healthcare professionals with an in-depth understanding of the clinical pharmacology, evidence base, and practical implications of intranasal biologic drug delivery systems.

Epidemiology / Disease Burden

The burden of chronic neurological, immunological, and infectious diseases is rising globally, with millions requiring biologic therapies. Conditions such as Alzheimer’s disease, multiple sclerosis, migraine, allergic rhinitis, and chronic rhinosinusitis represent substantial public health challenges. Despite proven efficacy, parenteral administration of biologics limits access and adherence, especially in resource-limited settings or among populations averse to injections. Intranasal delivery systems, by improving accessibility and tolerability, have the potential to impact disease burden significantly, particularly for CNS disorders where the blood-brain barrier (BBB) limits systemic biologic penetration.

Pathophysiology

The nasal cavity possesses a highly vascularized mucosa and is anatomically adjacent to the CNS through the olfactory and trigeminal neural pathways. This unique configuration allows for both local and systemic drug absorption, as well as direct nose-to-brain transport, bypassing the BBB. For biologics—large, hydrophilic molecules typically restricted by the BBB—intranasal delivery can facilitate CNS targeting. The physicochemical properties of the biologic, mucociliary clearance, enzymatic degradation, and formulation characteristics (e.g., mucoadhesive polymers, nanoparticles) critically influence pharmacokinetics and pharmacodynamics in the intranasal route.

Risk Factors

Several factors may influence the efficacy and safety of intranasal biologic drug delivery. Patient-specific risk factors include nasal pathology (e.g., chronic rhinitis, polyps), prior nasal surgery, mucosal atrophy, and concurrent respiratory infections. Environmental factors such as humidity, temperature, and allergens may also impact mucosal absorption. Drug-related risks include immunogenicity, local irritation, and potential for systemic adverse events, especially with repeated or high-dose administration. A thorough patient history and nasal examination are essential prior to initiation of intranasal biologic therapy.

Clinical Features

The clinical utility of intranasal biologic delivery is evident across diverse indications. For example, intranasal insulin and neuropeptides have shown promise in cognitive disorders, while monoclonal antibodies are being explored for migraine and allergic conditions. Key clinical considerations include rapid onset of action, non-invasiveness, and improved patient acceptability. However, clinicians must monitor for local adverse effects such as epistaxis, nasal dryness, and irritation, as well as systemic reactions depending on the biologic’s immunogenic profile.

Diagnosis

Appropriate patient selection for intranasal biologic therapy requires accurate diagnosis of the underlying condition, assessment of disease severity, and evaluation of previous treatment response. Nasal examination (anterior rhinoscopy, endoscopy) is recommended to exclude structural or inflammatory barriers to absorption. In CNS-targeting therapies, neuroimaging and cognitive assessments may be used to monitor response. Standardized protocols for baseline and follow-up evaluation enhance safety and optimize therapeutic outcomes.

Treatment & Management

Intranasal biologic treatment strategies are tailored to disease indication, drug characteristics, and patient factors. Dosing regimens are influenced by mucosal absorption kinetics, with some agents requiring multi-dose or sustained-release formulations. Patient education on administration technique, device handling, and adherence is critical for efficacy. Co-administration of permeation enhancers or bioadhesive agents may augment delivery, but clinicians must balance these with potential for mucosal toxicity. Regular monitoring for efficacy and adverse effects is essential, with prompt management of local or systemic reactions.

Recent Advances / Emerging Therapies

Recent advances in formulation science and device engineering have expanded the range of biologics amenable to intranasal delivery. Nanoparticle-encapsulation, cell-penetrating peptides, and mucoadhesive carriers enhance mucosal retention and trans-epithelial transport. Notably, intranasal administration of calcitonin gene-related peptide (CGRP) antagonists for migraine, monoclonal antibodies for allergic rhinitis, and even mRNA-based therapies are under active investigation. Clinical trials demonstrate promising pharmacokinetic profiles and patient-reported outcomes, although long-term data on safety and immunogenicity are ongoing. Regulatory agencies are increasingly recognizing the potential of these systems, evidenced by recent approvals and ongoing pipeline developments.

Guideline Recommendations

Current clinical guidelines are evolving to incorporate intranasal biologic delivery, particularly where it offers clear advantages over parenteral administration. The American Academy of Neurology and the European Headache Federation recommend intranasal CGRP antagonists for acute migraine management in selected patients. Similarly, intranasal monoclonal antibodies are endorsed for refractory allergic rhinitis and chronic rhinosinusitis with nasal polyps. Guidelines emphasize individualized patient assessment, counseling on correct administration, and vigilant monitoring for adverse events. Ongoing research will likely inform future updates and expand indications.

Conclusion

Intranasal delivery systems for biologic drugs represent a paradigm shift in clinical pharmacology, offering non-invasive, targeted, and potentially more effective therapeutic options for a range of diseases. While challenges remain—including variable mucosal absorption, immunogenicity, and local tolerability—recent advances in formulation and delivery technologies are rapidly addressing these limitations. Clinicians should remain informed of evolving evidence and guideline recommendations to optimize patient outcomes. The future of intranasal biologic therapy is promising, with continued research poised to expand its clinical utility across multiple specialties.